Emla 1 hour

PreclinicalSmall molecule

AAalborg University

Emla 1 hour is one of 2 small molecule programs targeting Pruritus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AestheticCompleted

AestheticPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Aesthetic

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

3 2

Emla 1 hour

AAalborg University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aesthetic1 trial

Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch

Completed·—·N/A·NCT04076865·26 enrolled

Pruritus1 trial

Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens

Completed·—·N/A·NCT04858360·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Emla 1 hour. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emla 1 hour compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emla 1 hour. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aalborg University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAalborg University

Emla 1 hour

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aesthetic1 trial

Pruritus1 trial

References

Drug Info

Quick Facts

Related News